2014-03-12 10:07:02 - Financial Assessment of the Global Pharmaceutical and Biotechnology Industry - a new market research report on companiesandmarkets.com
The biotechnology market and pharmaceutical markets have experienced lower margins over recent years. In the biotechnology industry, companies within the low revenue range and relatively new products have reports negative margins due to the increased costs associated with research and development and SG&A or selling and general expenses. Pharmaceutical companies have also witnessed smaller margins due to increasing competition from generics, pricing pressures and decreasing healthcare spend.
Companies which have a large portfolio of drugs have reported higher profitability within the pharmaceutical industry. To combat smaller margins and returns, pharmaceutical companies which have relatively small revenues are increasing their cash reserve as a percentage of their assets in order to protect their interests. In the biotechnology industry, all companies whether large
or small are increasing their cash reserves at the current time.
Interestingly, sales in 2012 were generally lower for both pharmaceutical and biotechnology companies and although this trend was reported, research and development costs and budgets were not considerably reduced over the same period.
The Key Issues/Challenges Faced by Industry Participants in the Pharmaceutical and Biotechnology Industry Include: The global economic slowdown; Regulatory compliance; Reducing profitability; Increasing R&D costs; Pricing pressures; Counterfeit business Financial Analysis of the Pharmaceutical and Biotechnology Industry.
This financial assessment study analyzes the financial ratios of public companies across the globe in the pharmaceutical and biotechnology industry. The research objectives are to rank companies based on their financial and risk management while also identifying key trends that can impact the performance of industry participants over the next year. Those analyzed include 718 publicly-listed pharmaceutical and 482 publicly-listed biotechnology companies across the globe. To assess the financial performance, ratios are divided into four categories: profitability, liquidity, activity (turnover), and solvency. Top performers in each industry are also highlighted.
Who will benefit?
Pharmaceutical & biotechnology companies
Venture capital investors
Sovereign wealth funds
Insurance funds and other members of the investing community
To analyze the financials of public companies in the global pharmaceutical and biotechnology industry.
To rank companies based on their financial and risk management.
To identify key trends and challenges that can impact the performance of industry participants over the next 12 months.
Click for report details: www.companiesandmarkets.com/Market/Healthcare-and-Medical/Market ..
Browse all Healthcare and Medical Market Research Reports www.companiesandmarkets.com/Market/Healthcare-and-Medical/Market ..
Browse all Healthcare and Medical Company Profile Reports www.companiesandmarkets.com/Market/Healthcare-and-Medical/Compan ..
Browse all Latest Market Research Reports www.companiesandmarkets.com/Market/All/Market-Research?aCode=f3f ..
Companiesandmarkets.com is a leading online business information aggregator with over 300,000 market reports and company profiles available to our clients. Our extensive range of reports are sourced from the leading publishers of business information and provide clients with the widest range of information available. In terms of company profiles, Companiesandmarkets.comâs online database allows clients access to market and corporate information to over 100,000 different companies. We provide clients with a fully indexed database of information where clients can find specific market reports on their niche industry sectors of interest.